US20030003117A1 - Hydrolyzed whole egg products & related methods - Google Patents
Hydrolyzed whole egg products & related methods Download PDFInfo
- Publication number
- US20030003117A1 US20030003117A1 US10/039,793 US3979302A US2003003117A1 US 20030003117 A1 US20030003117 A1 US 20030003117A1 US 3979302 A US3979302 A US 3979302A US 2003003117 A1 US2003003117 A1 US 2003003117A1
- Authority
- US
- United States
- Prior art keywords
- formulation
- oil
- substance
- mixture
- degrees celsius
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 225
- 238000009472 formulation Methods 0.000 claims abstract description 142
- 239000000126 substance Substances 0.000 claims abstract description 72
- 239000003974 emollient agent Substances 0.000 claims abstract description 25
- 239000003906 humectant Substances 0.000 claims abstract description 25
- 239000002537 cosmetic Substances 0.000 claims abstract description 14
- 239000003921 oil Substances 0.000 claims description 102
- 235000019198 oils Nutrition 0.000 claims description 102
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 50
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 42
- 238000010438 heat treatment Methods 0.000 claims description 36
- 238000010008 shearing Methods 0.000 claims description 36
- 239000000284 extract Substances 0.000 claims description 33
- 239000000839 emulsion Substances 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 235000011187 glycerol Nutrition 0.000 claims description 25
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 22
- 210000003205 muscle Anatomy 0.000 claims description 22
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 22
- 244000144725 Amygdalus communis Species 0.000 claims description 21
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 21
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 20
- 235000003222 Helianthus annuus Nutrition 0.000 claims description 20
- 235000009827 Prunus armeniaca Nutrition 0.000 claims description 20
- 244000018633 Prunus armeniaca Species 0.000 claims description 20
- 238000001816 cooling Methods 0.000 claims description 17
- 208000035484 Cellulite Diseases 0.000 claims description 16
- 206010049752 Peau d'orange Diseases 0.000 claims description 16
- 230000036232 cellulite Effects 0.000 claims description 16
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 15
- 235000021355 Stearic acid Nutrition 0.000 claims description 15
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 15
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 15
- 229960004274 stearic acid Drugs 0.000 claims description 15
- 239000008117 stearic acid Substances 0.000 claims description 15
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 14
- 239000008168 almond oil Substances 0.000 claims description 14
- 229940075529 glyceryl stearate Drugs 0.000 claims description 14
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 11
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 11
- 229960002216 methylparaben Drugs 0.000 claims description 11
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 11
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 11
- 229960003415 propylparaben Drugs 0.000 claims description 11
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 10
- 229940043375 1,5-pentanediol Drugs 0.000 claims description 10
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 claims description 10
- 241000208809 Carthamus Species 0.000 claims description 10
- 244000020518 Carthamus tinctorius Species 0.000 claims description 10
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 10
- 241000208818 Helianthus Species 0.000 claims description 10
- 244000020551 Helianthus annuus Species 0.000 claims description 10
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 10
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 10
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 10
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 10
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims description 10
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 10
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 10
- 229950011392 sorbitan stearate Drugs 0.000 claims description 10
- 229940031439 squalene Drugs 0.000 claims description 10
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 10
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 10
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 10
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 9
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 claims description 8
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 8
- 229940086555 cyclomethicone Drugs 0.000 claims description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000011732 tocopherol Substances 0.000 claims description 8
- 235000010384 tocopherol Nutrition 0.000 claims description 8
- 229960001295 tocopherol Drugs 0.000 claims description 8
- 229930003799 tocopherol Natural products 0.000 claims description 8
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 8
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 7
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 7
- 240000000467 Carum carvi Species 0.000 claims description 7
- 235000005747 Carum carvi Nutrition 0.000 claims description 7
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 7
- 206010000496 acne Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 229940041616 menthol Drugs 0.000 claims description 7
- 229940108325 retinyl palmitate Drugs 0.000 claims description 7
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 7
- 239000011769 retinyl palmitate Substances 0.000 claims description 7
- OEWBEINAQKIQLZ-CMRBMDBWSA-N [(2s)-2-[(2r)-3,4-bis(2-hexyldecanoyloxy)-5-oxo-2h-furan-2-yl]-2-(2-hexyldecanoyloxy)ethyl] 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OC[C@H](OC(=O)C(CCCCCC)CCCCCCCC)[C@H]1OC(=O)C(OC(=O)C(CCCCCC)CCCCCCCC)=C1OC(=O)C(CCCCCC)CCCCCCCC OEWBEINAQKIQLZ-CMRBMDBWSA-N 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 229940119168 tetrahexyldecyl ascorbate Drugs 0.000 claims description 6
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 5
- 241000723346 Cinnamomum camphora Species 0.000 claims description 5
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 claims description 5
- 241000341422 Geranium maculatum Species 0.000 claims description 5
- 241000592238 Juniperus communis Species 0.000 claims description 5
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 5
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 5
- 229960000846 camphor Drugs 0.000 claims description 5
- 229930008380 camphor Natural products 0.000 claims description 5
- 230000006870 function Effects 0.000 claims description 5
- 229960001047 methyl salicylate Drugs 0.000 claims description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 5
- 239000012188 paraffin wax Substances 0.000 claims description 5
- 229960004889 salicylic acid Drugs 0.000 claims description 5
- 230000029663 wound healing Effects 0.000 claims description 5
- 235000005979 Citrus limon Nutrition 0.000 claims description 4
- 244000131522 Citrus pyriformis Species 0.000 claims description 4
- 244000166124 Eucalyptus globulus Species 0.000 claims description 4
- 240000006028 Sambucus nigra Species 0.000 claims description 4
- 235000003142 Sambucus nigra Nutrition 0.000 claims description 4
- 229960000541 cetyl alcohol Drugs 0.000 claims description 4
- 229930002875 chlorophyll Natural products 0.000 claims description 4
- 235000019804 chlorophyll Nutrition 0.000 claims description 4
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims description 4
- 229940008099 dimethicone Drugs 0.000 claims description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 4
- 235000008995 european elder Nutrition 0.000 claims description 4
- 239000010651 grapefruit oil Substances 0.000 claims description 4
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 claims description 4
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 4
- 229940117336 parsley extract Drugs 0.000 claims description 4
- 235000019477 peppermint oil Nutrition 0.000 claims description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 4
- 229940112950 sage extract Drugs 0.000 claims description 4
- 235000020752 sage extract Nutrition 0.000 claims description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 3
- 240000000560 Citrus x paradisi Species 0.000 claims description 3
- 241000208152 Geranium Species 0.000 claims description 3
- 244000178870 Lavandula angustifolia Species 0.000 claims description 3
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 3
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 3
- 244000246386 Mentha pulegium Species 0.000 claims description 3
- RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 claims description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 3
- 235000001050 hortel pimenta Nutrition 0.000 claims description 3
- 239000001102 lavandula vera Substances 0.000 claims description 3
- 235000018219 lavender Nutrition 0.000 claims description 3
- 229940056211 paraffin Drugs 0.000 claims description 3
- 229960005323 phenoxyethanol Drugs 0.000 claims description 3
- 229940074543 primula veris extract Drugs 0.000 claims description 3
- 235000013772 propylene glycol Nutrition 0.000 claims description 3
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 claims description 3
- 235000007716 Citrus aurantium Nutrition 0.000 claims description 2
- 244000276331 Citrus maxima Species 0.000 claims description 2
- 235000001759 Citrus maxima Nutrition 0.000 claims description 2
- 240000003791 Citrus myrtifolia Species 0.000 claims description 2
- 235000000228 Citrus myrtifolia Nutrition 0.000 claims description 2
- 241001672694 Citrus reticulata Species 0.000 claims description 2
- 235000016646 Citrus taiwanica Nutrition 0.000 claims description 2
- 244000295848 Citrus x nobilis Species 0.000 claims description 2
- 235000017102 Citrus x nobilis Nutrition 0.000 claims description 2
- 241000531753 Geranium robertianum Species 0.000 claims description 2
- 241001479543 Mentha x piperita Species 0.000 claims description 2
- 240000006463 Pimenta racemosa Species 0.000 claims description 2
- 241000899950 Salix glauca Species 0.000 claims description 2
- 239000001140 aloe barbadensis leaf extract Substances 0.000 claims description 2
- 239000000294 eucalyptus globulus labille leaf/twig oil Substances 0.000 claims description 2
- 235000009733 malagueta Nutrition 0.000 claims description 2
- 239000001771 mentha piperita Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract description 8
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- 235000013601 eggs Nutrition 0.000 description 48
- 239000004615 ingredient Substances 0.000 description 16
- 238000005755 formation reaction Methods 0.000 description 10
- 229940016409 methylsulfonylmethane Drugs 0.000 description 8
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 8
- 210000003022 colostrum Anatomy 0.000 description 7
- 235000021277 colostrum Nutrition 0.000 description 7
- 238000007792 addition Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000010445 Lactoferrin Human genes 0.000 description 4
- 108010063045 Lactoferrin Proteins 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 4
- 235000021242 lactoferrin Nutrition 0.000 description 4
- 229940078795 lactoferrin Drugs 0.000 description 4
- NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 description 4
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 3
- 235000019489 Almond oil Nutrition 0.000 description 3
- 241000510672 Cuminum Species 0.000 description 3
- 241000220317 Rosa Species 0.000 description 3
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- XCWIEIVORUMFMV-UHFFFAOYSA-N methyl 4-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(O)C=C1.COC(=O)C1=CC=C(O)C=C1 XCWIEIVORUMFMV-UHFFFAOYSA-N 0.000 description 3
- NJBNJRILTKLNQZ-UHFFFAOYSA-N propyl 4-hydroxybenzoate Chemical compound CCCOC(=O)C1=CC=C(O)C=C1.CCCOC(=O)C1=CC=C(O)C=C1 NJBNJRILTKLNQZ-UHFFFAOYSA-N 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 101100279438 Caenorhabditis elegans egg-3 gene Proteins 0.000 description 2
- 235000007129 Cuminum cyminum Nutrition 0.000 description 2
- 235000017011 Mandorlo dulce Nutrition 0.000 description 2
- 244000076313 Mandorlo dulce Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 241000208317 Petroselinum Species 0.000 description 2
- 244000072254 Primula veris Species 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 2
- -1 Tetrahexyldecyl Chemical group 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940073669 ceteareth 20 Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- WUKXMJCZWYUIRZ-UHFFFAOYSA-N hexadecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(C)O WUKXMJCZWYUIRZ-UHFFFAOYSA-N 0.000 description 2
- 229940100460 peg-100 stearate Drugs 0.000 description 2
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- BBFCZCZRPXGONA-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol Chemical compound OCCN(CCO)CCO.OCCN(CCO)CCO BBFCZCZRPXGONA-UHFFFAOYSA-N 0.000 description 1
- VHBSECWYEFJRNV-UHFFFAOYSA-N 2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.OC(=O)C1=CC=CC=C1O VHBSECWYEFJRNV-UHFFFAOYSA-N 0.000 description 1
- PPOCFSJSVCAFQQ-UHFFFAOYSA-N 4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical compound C1CC2(C)C(=O)CC1C2(C)C.C1CC2(C)C(=O)CC1C2(C)C PPOCFSJSVCAFQQ-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 235000003840 Amygdalus nana Nutrition 0.000 description 1
- 101100279436 Caenorhabditis elegans egg-2 gene Proteins 0.000 description 1
- 235000008749 Caltha palustris Nutrition 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 235000014435 Mentha Nutrition 0.000 description 1
- 241001072983 Mentha Species 0.000 description 1
- 235000002343 Primula veris Nutrition 0.000 description 1
- 235000015924 Primula veris subsp veris Nutrition 0.000 description 1
- 241000220299 Prunus Species 0.000 description 1
- 235000011432 Prunus Nutrition 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940099898 chlorophyllin Drugs 0.000 description 1
- 235000019805 chlorophyllin Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000010648 geranium oil Substances 0.000 description 1
- 235000019717 geranium oil Nutrition 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 239000001851 juniperus communis l. berry oil Substances 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- RQFLGKYCYMMRMC-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O RQFLGKYCYMMRMC-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000014774 prunus Nutrition 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 239000000209 sambucus canadensis extract Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000002982 water resistant material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/982—Reproductive organs; Embryos, Eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/986—Milk; Derivatives thereof, e.g. butter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Definitions
- This invention relates to a product containing hydrolyzed whole eggs wherein the eggs are utilized as a carrier of the active ingredients in the product and is used to achieve the desired effects of the product. More specifically, the present invention relates to a hydrolyzed whole egg product for use as a cosmetic, pharmaceutical and/or medicinal product applicable for soothing sore muscles, expediting the healing and repairing process of the skin and reducing the visual appearance of cellulite.
- the present invention relates to a formulation comprising at least one hydrolyzed whole egg, at least one emollient substance and at least one humectant substance.
- hydrolyzed whole egg is defined as a whole egg consisting of egg white and the yolk, which through a special process has had the water extracted from it.
- emollient substance is defined as any natural or synthetic oil and their compound equivalents.
- humectant substance for the purposes of this invention is defined as glycerin and/or any other chemical of natural or synthetic origin.
- the humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof.
- the emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof.
- the formulation can be utilized as a cosmetic, cosmopharmaceutical and pharmaceutical formulation.
- the present invention relates to a formulation comprising: hydrolyzed egg and lactoferrin and/or colostrunml
- the present invention provides for a formulation comprising: hydrolyzed egg, at least one emollient substance, at least one humectant substance, and lactoferrin and/or colostrum.
- the colostrum is bovine colostrum.
- the present invention relates to a formulation comprising hydrolyzed whole egg and methyl sulfonyl methane (MSM).
- the formulation comprises hydrolyzed whole egg, at least one emollient substance, at least one humectant substance, and methyl sulfonyl methane (MSM).
- MSM methyl sulfonyl methane
- the present invention provides a formulation comprising hydrolyzed egg, methyl sulfonyl methane (MSM) and lactoferrin and/or colostrum.
- the formulation comprises: hydrolyzed whole egg, at least one emollient substance, at least one humectant substance, methyl sulfonyl methane (MSM) and lactoferrin and/or colostrum.
- the colostrum is bovine colostrum.
- the present invention relates to a cellulite formulation comprising at least one hydrolyzed whole egg, at least one emollient substance, at least one humectant substance and at least one aromatherapeutical substance.
- the humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof
- the emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof
- the aromatherapeutical substance is selected from a group consisting of Lavendula Angustifolia (Lavender) oil, Geranium
- the present invention relates to skin care formulation comprising at least one hydrolyzed whole egg, at least one emollient substance, at least one humectant substance and at least one skin nourishing/wound healing substance.
- the humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof.
- the emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof.
- the skin nourishing/wound healing substance is selected from a group consisting of aloe barbadensis leaf juice, white willow bark, and extracts thereof and mixtures thereof.
- skin nourishing/wound healing substance is defined as any material that will assist in or promote the skin healing and/or normalizing process.
- the skin care formulation further comprises an acne drug and the formulation functions as an acne formulation.
- the active drug is salicylic acid.
- the present invention also relates to a muscle soothing formulation comprising at least one hydrolyzed whole egg, at least one emollient substance, at least one humectant substance and a muscle soothing substance.
- the humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof
- the emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof
- the present invention relates to a hydrolyzed whole egg formulation manufactured by a method comprising: shearing a mixture of water, triethanolamine, glycerin and methyl paraben and heating the mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius; adding sweet almond oil, stearic acid, glyceryl stearate, and propylparaben to the mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius; adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; and upon formation of the emulsion, cooling the entire formulation.
- the method further comprising adding additional substances to said formulation during said cooling process.
- the formulation made by the above method may be utilized as a cosmetic, cosmopharmaceutical and pharmaceutical formulation depending on what additional substance(s) are added to the formulation during the cooling process.
- the present invention relates to a skin care formulation manufactured by a process comprising: shearing a mixture of water, triethanolamine, trisodium EDTA, glycerin and methyl paraben and heating the mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius; adding cetearyl alcohol, sweet almond oil, cetyl alcohol, stearic acid, glyceryl stearate, sorbitan stearate, tocopherol, retinyl palmitate, tetrahexyldecyl ascorbate and propylparaben to the mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius; adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; upon formation of the emulsion, cooling the entire formulation; and adding glycerin, salicylic acid and phenoxyethyano
- the present invention further relates to a muscle soothing formulation manufactured by a process comprising: shearing a mixture of water, triethanolamine, glycerin, trisodium and methyl paraben and heating the mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius; adding sweet almond oil, cetearyl alcohol, stearic acid, glyceryl stearate, cetyl lactate, tocopherol, retiryl palmitate, tetrahexyldecyl ascorbate and propylparaben to the mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius; adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; upon formation of the emulsion, cooling the entire formulation; and adding cyclomethicone, menthol, methyl salicylate, eucalyptus globules oil
- the present invention provides cosmetic, cosmopharmaceutical and pharmaceutical formulations containing hydrolyzed whole egg(s).
- Whole eggs are a great source of nutrients and function as carriers/deliverers of various active and inactive ingredients to the respective human/animal bodily components, organs, tissues, cells, etc.
- the present invention utilizes chicken eggs but can use any and all types of eggs, including but not limited to, poultry and reptile eggs.
- the formulation of the present invention includes, but is not limited to, a skin care formulation, a muscle soothing formulation and a cellulite formulation.
- a skin care formulation a muscle soothing formulation
- a cellulite formulation There are three unique products, discussed in detail below, that have radically different functions ranging from soothing sore muscles, to expediting the repairing process of the skin and reducing the visual appearance of cellulite.
- the common factor that is shared by all of these products is the use of the hydrolyzed whole egg to achieve the desired effects in each case and the unique processing method of incorporating the egg within the formulation and allowing the whole egg to act as a carrier of the active ingredients in each case.
- the skin care formulation of the present invention is designed to treat eczema, psoriasis, sunburns, razor burns, blisters, acne, insect bites, burns, cuts, bruises and dry skin.
- the skin care formulation of the present invention may be manufactured by the following process: shearing a mixture of water, triethanolamine, trisodium EDTA, glycerin and methyl paraben and heating the mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius; adding cetearyl alcohol, sweet almond oil, cetyl alcohol, stearic acid, glyceryl stearate, sorbitan stearate, tocopherol, retinyl palmitate, tetrahexyldecyl ascorbate and propylparaben to the mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius; adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the
- Table 1 below indicates the ingredients of the skin care product of the present invention including the sequence of addition into the formulation and the % W/W of each ingredient relate to the entire formulation.
- TABLE 1 Skin Care Ingredients for HEALFAST TM Formulation SEQUENCE TRADENAME INCI NAME % W/W 1 Water Water (Aqua) 50-80 1 Triethanolamine 99% Triethanolamine 0.05-5.00 1 Hampene Na3T Trisodium EDTA 0.10-1.00 1 Glycerin Glycerin 0.10-3.00 1 Methylparaben Methylparaben 0.10-5.00 2 Lipowax D Cetearyl Alcohol 0.10-5.00 (and) Ceteareth-20 2 Sweet Almond Oil Sweet Almond 0.10-10.00 (Prunus Amygdalus Dulcis) Oil 2 Lipocol Cetyl Alcohol 0.10-5.00 2 Stearic Acid XXX Stearic Acid 0.10-5.00 2 Lipomulse 165 Glyceryl Stearate 0.10-5.00 (and) PEG-100 Stea
- the above skin care formulation may be embedded or incorporated onto a patch or bandage, which can be adhered onto the target area of the human body (for example, a cut or laceration on the forearm).
- the patch or bandage may be of any shape or size and it comprises an adhesive strip for attaching the pad or bandage onto the human user and a pad containing the skin care formulation, which is placed directly upon the target area.
- the patch or bandage may further comprise removable tabs (which are removed at the moment of use) and a sterile wrapper or packaging.
- the skin care formulation may be embedded or incorporated onto or into the pad through any and all techniques utilized in embedding medicament, ointment or other substances.
- the pad and adhesive strip may be constructed of any stretchable, bendable or breathable material, including various fabrics.
- the pad and adhesive strip may also be constructed of water resistant materials.
- the pad may be an absorbent cushion pad that has excellent drainage properties.
- the patch or bandage may be dermatologically tested and hypoallergenic.
- the muscle soothing formulation and cellulite formulation discussed below may also be embedded or incorporated onto patches or bandages.
- the muscle soothing and cellulite patches or bandages may also be attached onto the target area of the human anatomy (for example, the cellulite patch may be placed upon the woman's thighs or the muscle soothing patch may be adhered to an aching back or foot).
- the patches may also contain concentrated amount of the formulation and based upon the formulation, the patch or bandage may be designed to be used for hours or for days and even, for weeks.
- the patches or bandages are utilized to apply the formulation directly onto target areas and may provide a less messy alternative to direct application of the formulation onto the user's body. The patches will also prevent contact of the formulation with the user's clothing.
- the muscle soothing formulation of the present invention is designed to treat muscle aches and pains, and is applicable for all muscle parts and joints.
- the muscle soothing formulation of the present invention may be manufactured by the following method: shearing a mixture of water, triethanolamine, glycerin, trisodium and methyl paraben and heating the mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius; adding sweet almond oil, cetearyl alcohol, stearic acid, glyceryl stearate, cetyl lactate, tocopherol, retiryl palmitate, tetrahexyldecyl ascorbate and propylparaben to the mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius; adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; upon formation of the emulsion, cooling the entire formulation; and adding cyclomethicone, menthol
- Sequence #1 is loaded under adequate shear and heated from about 76 degrees Celsius to about 78 degrees Celsius. (For purposes of this invention, adequate shear is defined as from about 800 to about 2000 RPMs).
- Sequence #2 is then loaded to the kettle and is further heated from about 82 degrees Celsius to about 86 degrees Celsius, with adequate shear. (For purposes of this invention, adequate shear is defined as from about 800 to about 2000 RPMs).
- the cooling process begins and the process may then be continued until the phases of the formula are further added.
- the “Eggosome” or “Ovasome” of the present invention is capable of carrying and delivering any and all types of ingredients, active and inactive, natural and synthetic, drugs, nutrients, or bioactives.
- the formulation of the present invention can also be modified to function as a cosmetic and/or pharmaceutical formulation depending on the additional ingredients added to this unique manufacturing process and depending on what ingredients may be desired to be delivered to a human or animal target.
- the formulation of the present invention may be simply applied to the skin and the semi-permeable nature of the skin will allow entrance of the formulation and the “Eggosome” or “Ovasome” will then be able to deliver the desired material to the desired target. Since the “Eggosome” or “Ovasome” is capable of carrying various ingredients including active drugs, the formulation of the present invention may also have medicinal applications.
- the present invention may also include accelerated healing ingredients that may be applied to adhesive patches and bandages for commercial and hospital use.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
Abstract
The present invention provides a formulation comprising hydrolyzed whole egg, an emollient substance and a humectant substance; and provides a method of incorporating a hydrolyzed whole egg into a cosmetic, pharmaceutical and medicinal formulation wherein the hydrolyzed whole egg acts as a nutrient source and as a carrier of the active ingredients in the formulation to desired bodily targets.
Description
- This application is related to Provisional U.S. Application Serial No. 60/298,874, entitled “A SKIN CARE PRODUCT AND A METHOD OF PRODUCING SAME” which was filed on Jun. 18, 2001.
- 1. Field of the Invention
- This invention relates to a product containing hydrolyzed whole eggs wherein the eggs are utilized as a carrier of the active ingredients in the product and is used to achieve the desired effects of the product. More specifically, the present invention relates to a hydrolyzed whole egg product for use as a cosmetic, pharmaceutical and/or medicinal product applicable for soothing sore muscles, expediting the healing and repairing process of the skin and reducing the visual appearance of cellulite.
- 2. Description of the Related Art
- There are numerous cosmetic and skin care products that use components of eggs as major ingredients in their formulation. For example, some cosmetic or skin care products use egg whites in their formulation. Other cosmetic and skin care products use extracts of yokes in their formulation. The use of whole egg has never been achieved since the mixing and/or shearing process of the manufacturing of the product will cause the egg components to coagulate and form mayonnaise. There have also been problems with incorporating the whole egg in the formations since the shearing and heating process of most processes have denatured the proteins in the eggs and have inactivated the active ingredients in the egg which provides for its excellent carrier/delivery properties. In addition, there are no cosmetic, medicinal, pharmaceutical and/or cosmopharmaceutical product that utilize whole eggs as carriers for their active ingredients.
- In one embodiment, the present invention relates to a formulation comprising at least one hydrolyzed whole egg, at least one emollient substance and at least one humectant substance. The term “hydrolyzed whole egg” is defined as a whole egg consisting of egg white and the yolk, which through a special process has had the water extracted from it. For purposes of this invention, the term “emollient substance” is defined as any natural or synthetic oil and their compound equivalents. The term “humectant substance” for the purposes of this invention is defined as glycerin and/or any other chemical of natural or synthetic origin. In another embodiment, the humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof. In yet another embodiment, the emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof. In still another embodiment, the formulation can be utilized as a cosmetic, cosmopharmaceutical and pharmaceutical formulation.
- In a further embodiment, the present invention relates to a formulation comprising: hydrolyzed egg and lactoferrin and/or colostrunml In still a further embodiment, the present invention provides for a formulation comprising: hydrolyzed egg, at least one emollient substance, at least one humectant substance, and lactoferrin and/or colostrum. In still another embodiment, the colostrum is bovine colostrum.
- In yet a further embodiment, the present invention relates to a formulation comprising hydrolyzed whole egg and methyl sulfonyl methane (MSM). In still yet a frither embodiment, the formulation comprises hydrolyzed whole egg, at least one emollient substance, at least one humectant substance, and methyl sulfonyl methane (MSM). In a further embodiment, the present invention provides a formulation comprising hydrolyzed egg, methyl sulfonyl methane (MSM) and lactoferrin and/or colostrum. In another further embodiment, the formulation comprises: hydrolyzed whole egg, at least one emollient substance, at least one humectant substance, methyl sulfonyl methane (MSM) and lactoferrin and/or colostrum. In still another embodiment, the colostrum is bovine colostrum.
- In still yet another formulation, the present invention relates to a cellulite formulation comprising at least one hydrolyzed whole egg, at least one emollient substance, at least one humectant substance and at least one aromatherapeutical substance. In a further embodiment, the humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof In yet a further embodiment, the emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof In still yet a further embodiment, the aromatherapeutical substance is selected from a group consisting of Lavendula Angustifolia (Lavender) oil, Geranium Maculatum Oil, Citrus Grandis (Grapefruit) oil, Juniperus Communis Oil, Pimenta Acris (Bay) Oil, Lavendula Hybrida, Geranium Robertianum, Geranium Thunbergil, Citrus Aurantium Dulsis (Orange) Oil, Citrus Nobilis (Mandarin Orange) Oil, Citrus Limonum (Lemon) Oil and extracts thereof and mixtures thereof. For purposes of this invention, the term “aromatherapeutical substance” is defined as a combination of pure essental oils with aromatic properties.
- In another further embodiment, the present invention relates to skin care formulation comprising at least one hydrolyzed whole egg, at least one emollient substance, at least one humectant substance and at least one skin nourishing/wound healing substance. In still another further embodiment, the humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof. In yet another further embodiment, the emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof.
- In still yet another further embodiment, the skin nourishing/wound healing substance is selected from a group consisting of aloe barbadensis leaf juice, white willow bark, and extracts thereof and mixtures thereof. The term “skin nourishing/wound healing substance” is defined as any material that will assist in or promote the skin healing and/or normalizing process. In another embodiment, the skin care formulation further comprises an acne drug and the formulation functions as an acne formulation. In still another embodiment, the active drug is salicylic acid.
- In a further embodiment, the present invention also relates to a muscle soothing formulation comprising at least one hydrolyzed whole egg, at least one emollient substance, at least one humectant substance and a muscle soothing substance. In still a further embodiment, the humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof In yet a further embodiment, the emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof
- In still yet a further embodiment, the muscle soothing substance comprises a blend of Menthol, Methyl Salicylate, Eucalyptus Globulus Oil, Camphor, and Mentha Piperita (Peppermint) Oil. For purposes of this invention, the “muscle soothing substance” is defined as any active ingredient or pure substance that can penetrate and cause sensation to the muscle tissue.
- In another further embodiment, the present invention relates to a hydrolyzed whole egg formulation manufactured by a method comprising: shearing a mixture of water, triethanolamine, glycerin and methyl paraben and heating the mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius; adding sweet almond oil, stearic acid, glyceryl stearate, and propylparaben to the mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius; adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; and upon formation of the emulsion, cooling the entire formulation. In still another further embodiment, the method further comprising adding additional substances to said formulation during said cooling process. In yet another further embodiment, the formulation made by the above method may be utilized as a cosmetic, cosmopharmaceutical and pharmaceutical formulation depending on what additional substance(s) are added to the formulation during the cooling process.
- In another embodiment, the present invention relates to a skin care formulation manufactured by a process comprising: shearing a mixture of water, triethanolamine, trisodium EDTA, glycerin and methyl paraben and heating the mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius; adding cetearyl alcohol, sweet almond oil, cetyl alcohol, stearic acid, glyceryl stearate, sorbitan stearate, tocopherol, retinyl palmitate, tetrahexyldecyl ascorbate and propylparaben to the mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius; adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; upon formation of the emulsion, cooling the entire formulation; and adding glycerin, salicylic acid and phenoxyethyanol and shearing the entire formulation. In still another embodiment, the formulation made by the above process may be used for acne skin care.
- In yet another embodiment, the present invention further relates to a muscle soothing formulation manufactured by a process comprising: shearing a mixture of water, triethanolamine, glycerin, trisodium and methyl paraben and heating the mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius; adding sweet almond oil, cetearyl alcohol, stearic acid, glyceryl stearate, cetyl lactate, tocopherol, retiryl palmitate, tetrahexyldecyl ascorbate and propylparaben to the mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius; adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; upon formation of the emulsion, cooling the entire formulation; and adding cyclomethicone, menthol, methyl salicylate, eucalyptus globules oil, camphor, peppermint oil, pheroxyethanol and chlorophyll and shearing the entire formulation.
- In a further embodiment, the present invention relates to a cellulite formulation manufactured by a process comprising: shearing a mixture of water, triethanolamine, glycerin, propylene glycol and methyl paraben and heating the mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius; adding sweet almond oil, cetyl lactate, stearic acid, paraffin, sorbitan stearate, glyceryl stearate, cyclomethicone and dimethicone copotyol, and propylparaben to said mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius; adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; upon formation of the emulsion, cooling the entire formulation; and adding grapefruit oil, lavender oil, geranium maculatum oil, juniperus communis oil, cumen extract, sambucus nigra extract, caraway extract, sage extract, parsley extract, primula veris extract and phenoxyethanol and shearing the entire formulation.
- In still a further embodiment, the present invention relates to a method of manufacturing a formulation, the method comprising: shearing at least one emollient substance and at least one humectant substance; adding at least one hydrolyzed whole egg to the oil phase of the mixture and then adding the oil phase to the water phase to form an emulsion; and upon formation of the emulsion, cooling the formulation. In yet a further embodiment, the humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof In yet another further embodiment, the emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof. In still yet a further embodiment, the formulation may be used as a cosmetic, cosmopharmaceutical and pharmaceutical formulation depending on what additional substance(s) are added to the formulation.
- As required, detailed embodiments of the present invention are disclosed herein; however, it is to be understood that the disclosed embodiments are merely exemplary of the invention that may be embodied in various forms. The figures are not necessary to scale, some features may be exaggerated to show details of particular components. Therefore, specific structural and functional details disclosed herein are not to be interpreted as limiting, but merely as a basis for the claims and as a representative basis for teaching one skilled in the art to variously employ the present invention.
- The present invention provides cosmetic, cosmopharmaceutical and pharmaceutical formulations containing hydrolyzed whole egg(s). Whole eggs are a great source of nutrients and function as carriers/deliverers of various active and inactive ingredients to the respective human/animal bodily components, organs, tissues, cells, etc. The present invention utilizes chicken eggs but can use any and all types of eggs, including but not limited to, poultry and reptile eggs.
- The formulation of the present invention includes, but is not limited to, a skin care formulation, a muscle soothing formulation and a cellulite formulation. There are three unique products, discussed in detail below, that have radically different functions ranging from soothing sore muscles, to expediting the repairing process of the skin and reducing the visual appearance of cellulite. The common factor that is shared by all of these products is the use of the hydrolyzed whole egg to achieve the desired effects in each case and the unique processing method of incorporating the egg within the formulation and allowing the whole egg to act as a carrier of the active ingredients in each case.
- The specific examples below will enable the present invention to be better understood. However, they are given merely by way of guidance and do not imply any limitation to this invention.
- HEALFAST™ Skin Care Formulation
- The skin care formulation of the present invention is designed to treat eczema, psoriasis, sunburns, razor burns, blisters, acne, insect bites, burns, cuts, bruises and dry skin. The skin care formulation of the present invention, may be manufactured by the following process: shearing a mixture of water, triethanolamine, trisodium EDTA, glycerin and methyl paraben and heating the mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius; adding cetearyl alcohol, sweet almond oil, cetyl alcohol, stearic acid, glyceryl stearate, sorbitan stearate, tocopherol, retinyl palmitate, tetrahexyldecyl ascorbate and propylparaben to the mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius; adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; upon formation of the emulsion, cooling the entire formulation; and adding glycerin, salicylic acid and phenoxyethyanol and shearing the entire formulation. Table 1 below indicates the ingredients of the skin care product of the present invention including the sequence of addition into the formulation and the % W/W of each ingredient relate to the entire formulation.
TABLE 1 Skin Care Ingredients for HEALFAST ™ Formulation SEQUENCE TRADENAME INCI NAME % W/W 1 Water Water (Aqua) 50-80 1 Triethanolamine 99% Triethanolamine 0.05-5.00 1 Hampene Na3T Trisodium EDTA 0.10-1.00 1 Glycerin Glycerin 0.10-3.00 1 Methylparaben Methylparaben 0.10-5.00 2 Lipowax D Cetearyl Alcohol 0.10-5.00 (and) Ceteareth-20 2 Sweet Almond Oil Sweet Almond 0.10-10.00 (Prunus Amygdalus Dulcis) Oil 2 Lipocol Cetyl Alcohol 0.10-5.00 2 Stearic Acid XXX Stearic Acid 0.10-5.00 2 Lipomulse 165 Glyceryl Stearate 0.10-5.00 (and) PEG-100 Stearate 2 Sorbitan Stearate Sorbitan Stearate 0.10-5.00 2 Covi-ax T-50 Tocopherol 0.01-1.00 2 Vitamin A Palmitate Retinyl Palmitate 0.10-3.00 2 BVOSC (Barnet) Tetrahexyldecyl 0.10-3.00 Ascorbate 2 Propylparaben Propylparaben 0.10-3.00 2 Hydrolyzed Whole Hydrolyzed Whole 0.10-10.00 Egg Egg 3 Glycerin Glycerin 0.10-5.00 3 Salicylic Acid Salicylic Acid 0.01-0.49 4 Emmeressence 1160 Phenoxyethyanol 0.10-3.00 Rose - In another embodiment of the present invention, the above skin care formulation (HEALFAST™) may be embedded or incorporated onto a patch or bandage, which can be adhered onto the target area of the human body (for example, a cut or laceration on the forearm). The patch or bandage may be of any shape or size and it comprises an adhesive strip for attaching the pad or bandage onto the human user and a pad containing the skin care formulation, which is placed directly upon the target area. The patch or bandage may further comprise removable tabs (which are removed at the moment of use) and a sterile wrapper or packaging.
- The skin care formulation may be embedded or incorporated onto or into the pad through any and all techniques utilized in embedding medicament, ointment or other substances. The pad and adhesive strip may be constructed of any stretchable, bendable or breathable material, including various fabrics. The pad and adhesive strip may also be constructed of water resistant materials. The pad may be an absorbent cushion pad that has excellent drainage properties. The patch or bandage may be dermatologically tested and hypoallergenic.
- In still another embodiment, the muscle soothing formulation and cellulite formulation discussed below may also be embedded or incorporated onto patches or bandages. Like the HEALFAST™ patches or bandages, the muscle soothing and cellulite patches or bandages may also be attached onto the target area of the human anatomy (for example, the cellulite patch may be placed upon the woman's thighs or the muscle soothing patch may be adhered to an aching back or foot). The patches may also contain concentrated amount of the formulation and based upon the formulation, the patch or bandage may be designed to be used for hours or for days and even, for weeks. The patches or bandages are utilized to apply the formulation directly onto target areas and may provide a less messy alternative to direct application of the formulation onto the user's body. The patches will also prevent contact of the formulation with the user's clothing.
- ULTRA SOOTHE™ Muscle Soothing Formulation
- The muscle soothing formulation of the present invention is designed to treat muscle aches and pains, and is applicable for all muscle parts and joints. The muscle soothing formulation of the present invention may be manufactured by the following method: shearing a mixture of water, triethanolamine, glycerin, trisodium and methyl paraben and heating the mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius; adding sweet almond oil, cetearyl alcohol, stearic acid, glyceryl stearate, cetyl lactate, tocopherol, retiryl palmitate, tetrahexyldecyl ascorbate and propylparaben to the mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius; adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; upon formation of the emulsion, cooling the entire formulation; and adding cyclomethicone, menthol, methyl salicylate, eucalyptus globules oil, camphor, peppermint oil, pheroxyethanol and chlorophyll and shearing the entire formulation Table 2 below indicates the ingredients of the muscle soothing product of the present invention including the sequence of addition into the formulation and the % W/W of each ingredient relate to the entire formulation.
TABLE 2 Muscle Soothing Ingredients for ULTRA SOOTHE ™ Formulation SEQUENCE TRADENAME INCI NAME % W/W 1 Water Water (Aqua) 20-60 1 Glycerin Glycerin 0.10-10.00 1 Methylparaben Methylparaben 0.10-0.30 1 Hampene Na3T Trisodium EDTA 0.10-0.30 1 Triethanolamine Triethanolamine 0.01-3.00 2 Stearic Acid Stearic Acid 0.50-5.00 2 Lipowax D Cetearyl Alcohol 2.50-7.50 (and) Ceteareth-20 2 Almond Oil Sweet Almond 5.0-15.00 (Prunus Amygdalus Dulcis) Oil 2 Lipomulse 165 Glyceryl Stearate 3.50 (and) PEG-100 Stearate 2 Ceraphyl 28 Cetyl Lactate 0.30-4.00 2 Hydrolyzed Whole Hydrolyzed Whole 0.10-10.00 Egg Egg 2 Covi-ax T-50 Tocopherol 0.10-0.50 2 Vitamin A Palmitate Retinyl Palmitate 0.10-0.50 2 BVOSC (Barnet) Tetrahexyldecyl 0.10-1.00 Ascorbate 2 Propylparaben Propylparaben 0.10-0.30 3 Sepigel 305 Polyacrylamide 2-5 (and) C13-14 Isoparaffin (and) Laureth-7 4 Dow Corning 345 Cyclomethicone 1.00-5.00 Fluid 5 Menthol Menthol 2-10 5 Methyl Salicylate Methyl Salcylate 2-10 5 Eucalyptus Oil Eucalyptus Globulus 0.10-5.00 Oil 5 Camphor Camphor 2-10 5 Peppermint Oil Peppermint (Mentha 0.10-5.00 Piperita) Oil 6 Emmeressence 1160 Phenoxyethyanol 0.10-3.00 Rose 7 Chlorophyllin Coper Chlorophyll q.s. Complex - CELLUTONE™ Cellulite Formulation
- The cellulite formulation of the present invention is designed to reduce the visual appearance of cellulite. The cellulite formulation of the present invention may be manufactured by the following method: shearing a mixture of water, triethanolamine, glycerin, propylene glycol and methyl paraben and heating the mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius; adding sweet almond oil, cetyl lactate, stearic acid, paraffin, sorbitan stearate, glyceryl stearate, cyclomethicone and dimethicone copotyol, and propylparaben to said mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius; adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; upon formation of the emulsion, cooling the entire formulation; and adding grapefruit oil, lavender oil, geranium maculatum oil, juniperus communis oil, cumen extract, sambucus nigra extract, caraway extract, sage extract, parsley extract, primula veris extract and phenoxyethanol and shearing the entire formulation. Table 3 below indicates the ingredients of the cellulite product of the present invention including the sequence of addition into the formulation and the % W/W of each ingredient relate to the entire formulation.
TABLE 3 Cellulite Ingredients for CELLUTONE ™ Formulation SEQUENCE TRADENAME INCI NAME % W/W 1 Water Water (Aqua) 40-60 1 Triethanolamine 99% Triethanolamine 0.30-3.00 1 Carbowax 400 PEG-8 0.10-10.00 1 Glycerin Glycerin 0.50-5.00 1 Propylene Glycol Propylene Glycol 1.00-4.00 1 Methylparaben Methylparaben 0.10-1.00 2 Lipo GMS 450 Glyceryl Stearate 0.25-5.00 2 Sweet Almond Oil Sweet Almond 0.60-6.00 (Prunus Aniygdalus Dulcis) Oil 2 Ceraphyl 28 Cetyl Lactate 0.50-5.00 2 Stearic Acid XXX Stearic Acid 0.50-5.00 2 Paraffin Paraffin 0.50-5.00 2 Sorbitan Stearate Sorbitan Stearate 0.50-5.00 2 Propylparaben Propylparaben 0.10-5.00 2 Dow Corning 3225C Cyclomethicone 0.10-10.00 (and) Dimethicone Copotyol 2 Hydrolyzed Whole Hydrolyzed Whole 0.10-10.00 Egg Egg 3 Grapefruit Oil Grapefruit (Citrus) 0.10-2.00 Gandis) Oil 3 Lavender Oil Lavender 0.50-5.00 (Lavendula Angustifoli) Oil 3 Geranium Oil Geranium 0.50-5.00 Maculatum Oil 3 Juniperberry Oil Juniperus 0.50-5.00 Communis Oil 4 Cumin Extract Cumin (Cuminum 0.50-5.00 Cyminum) Extract 4 Elderflower Extract Sambucus Nigra 0.50-5.00 Extract 4 Caraway Extract Caraway (Carum 0.50-5.00 Carvi) Extract 4 Sage Extract Sage (Salvia 0.50-5.00 Officinalis) Extract 4 Parsley Extract Parsley (Carum 0.50-5.00 Petroselinum) Extract 4 Cowslip Extract Primula Veris 0.50-5.00 Extract 5 Emmeressence 1160 Phenoxyethyanol 0.10-3.00 Rose - Below is a manufacturing process that is suitable for all three products which depicts a unique method of the addition of the water-soluble egg into the oil phase of the formulation at relatively high temperatures. The process allows the egg to encapsulate the oils and permits the formulation containing the encapsulated egg to penetrate into the skin and deliver the active ingredients. The egg with the encapsulated oils is termed “Eggosomes” and is formed prior to the emulsification process.
- The manufacturing process of the present invention is applicable to Examples 1-3 of the present invention and relates to the ingredients and sequence of additions illustrated in Tables 1-3. The manufacturing procedure is as follows:
- Into a stainless steel, jacketed kettle equipped with at least one high shear mixer and at least one planetary mixer, Sequence #1 is loaded under adequate shear and heated from about 76 degrees Celsius to about 78 degrees Celsius. (For purposes of this invention, adequate shear is defined as from about 800 to about 2000 RPMs).
- After adequate shearing and heating of Sequence #1, Sequence #2 is then loaded to the kettle and is further heated from about 82 degrees Celsius to about 86 degrees Celsius, with adequate shear. (For purposes of this invention, adequate shear is defined as from about 800 to about 2000 RPMs).
- When the kettle reaches its optimum temperatures, the hydrolyzed whole egg is added to the oil phase kettle and the heating is stopped. The hydrolyzed egg is gently stirred into the oil, and is evenly coated with the oil, but not burned (this is known as the formation of the “Eggosome”). Within seconds, the oil phase is added to the water phase, thus completing the “Eggosome” or carrier vehicle. The emulsion is formed. The temperature and energy are carefully monitored to ensure that a small particle is formed (this can be confirmed under the microscope).
- Once the emulsion is formed, the cooling process begins and the process may then be continued until the phases of the formula are further added.
- The “Eggosome” or “Ovasome” of the present invention is capable of carrying and delivering any and all types of ingredients, active and inactive, natural and synthetic, drugs, nutrients, or bioactives. The formulation of the present invention can also be modified to function as a cosmetic and/or pharmaceutical formulation depending on the additional ingredients added to this unique manufacturing process and depending on what ingredients may be desired to be delivered to a human or animal target. In one embodiment, the formulation of the present invention may be simply applied to the skin and the semi-permeable nature of the skin will allow entrance of the formulation and the “Eggosome” or “Ovasome” will then be able to deliver the desired material to the desired target. Since the “Eggosome” or “Ovasome” is capable of carrying various ingredients including active drugs, the formulation of the present invention may also have medicinal applications. The present invention may also include accelerated healing ingredients that may be applied to adhesive patches and bandages for commercial and hospital use.
- Numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the attendant claims attached hereto, this invention may be practiced otherwise than as specifically disclosed herein.
Claims (35)
1. A formulation comprising at least one hydrolyzed whole egg, at least one emollient substance and at least one humectant substance.
2. The formulation of claim 1 wherein said humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof.
3. The formulation of claim 1 wherein said emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil, synthetic oils and extracts thereof and mixtures thereof.
4. The formulation of claim 1 wherein said formulation is a cosmetic formulation.
5. The formulation of claim 1 wherein said formulation is a cosmopharmaceutical formulation.
6. The formulation of claim 1 wherein said formulation is a pharmaceutical formulation.
7. A cellulite formulation comprising at least one hydrolyzed whole egg, at least one emollient substance, at least one humectant substance and at least one aromatherapeutical substance.
8. The formulation of claim 7 wherein said humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof.
9. The formulation of claim 7 wherein said emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof.
10. The formulation of claim 7 wherein said aromatherapeutical substance is selected from a group consisting of Lavendula Angustifolia (Lavender) oil, Geranium Maculatum Oil, Citrus Grandis (Grapefruit) oil, Juniperus Communis Oil, Pimenta Acris (Bay) Oil, Lavendula Hybrida, Geranium Robertianum, Geranium Thunbergil, Citrus Aurantium Dulsis (Orange) Oil, Citrus Nobilis (Mandarin Orange) Oil, Citrus Limonum (Lemon) Oil and extracts thereof and mixtures thereof.
11. A skin care formulation comprising at least one hydrolyzed whole egg, at least one emollient substance, at least one humectant substance and at least one skin nourishing/wound healing substance.
12. The formulation of claim 11 wherein said humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof.
13. The formulation of claim 11 wherein said emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof.
14. The formulation of claim 11 wherein said skin nourishing/wound healing substance is selected from a group consisting of aloe barbadensis leaf juice, white willow bark, and extracts thereof and mixtures thereof.
15. The formulation of claim 11 further comprising an acne drug and said formulation functions as an acne formulation.
16. The formulation of claim 15 wherein said active drug is salicylic acid.
17. A muscle soothing formulation comprising at least one hydrolyzed whole egg, at least one emollient substance, at least one humectant substance and a muscle soothing substance.
18. The formulation of claim 17 wherein said humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof.
19. The formulation of claim 17 said emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof.
20. The formulation of claim 17 wherein said muscle soothing substance comprises a blend of Menthol, Methyl Salicylate, Eucalyptus Globulus Oil, Camphor, and Mentha Piperita (Peppermint) Oil.
21. A hydrolyzed whole egg formulation manufactured by a method comprising:
shearing a mixture of water, triethanolamine, glycerin and methyl paraben and heating said mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius;
adding sweet almond oil, stearic acid, glyceryl stearate, and propylparaben to said mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius;
adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion; and
upon formation of the emulsion, cooling the entire formulation.
22. The formulation of claim 21 further comprising adding additional substances to said formulation during said cooling process.
23. The formulation of claim 21 wherein said formulation is a cosmetic formulation.
24. The formulation of claim 21 wherein said formulation is a cosmopharmaceutical formulation.
25. The formulation of claim 21 wherein said formulation is a pharmaceutical formulation.
26. A skin care formulation manufactured by a process comprising:
shearing a mixture of water, triethanolamine, trisodium EDTA, glycerin and methyl paraben and heating said mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius;
adding cetearyl alcohol, sweet almond oil, cetyl alcohol, stearic acid, glyceryl stearate, sorbitan stearate, tocopherol, retinyl palmitate, tetrahexyldecyl ascorbate and propylparaben to said mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius;
adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion;
upon formation of the emulsion, cooling the entire formulation; and
adding glycerin, salicylic acid and phenoxyethyanol and shearing the entire formulation.
27. The formulation of claim 26 wherein said formulation is used for acne skin care.
28. A muscle soothing formulation manufactured by a process comprising:
shearing a mixture of water, triethanolamine, glycerin, trisodium and methyl paraben and heating said mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius;
adding sweet almond oil, cetearyl alcohol, stearic acid, glyceryl stearate, cetyl lactate, tocopherol, retiryl palmitate, tetrahexyldecyl ascorbate and propylparaben to said mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius;
adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion;
upon formation of the emulsion, cooling the entire formulation; and
adding cyclomethicone, menthol, methyl salicylate, eucalyptus globules oil, camphor, peppermint oil, pheroxyethanol and chlorophyll and shearing the entire formulation.
29. A cellulite formulation manufactured by a process comprising:
shearing a mixture of water, triethanolamine, glycerin, propylene glycol and methyl paraben and heating said mixture to a temperature from about 70 degrees Celsius to about 80 degrees Celsius;
adding sweet almond oil, cetyl lactate, stearic acid, paraffin, sorbitan stearate, glyceryl stearate, cyclomethicone and dimethicone copotyol, and propylparaben to said mixture and shearing and heating the entire mixture to a temperature from about 90 degrees Celsius to about 100 degrees Celsius;
adding a hydrolyzed egg to the oil phase of the entire mixture while stopping the heating process and adding the oil phase to the water phase to form an emulsion;
upon formation of the emulsion, cooling the entire formulation; and
adding grapefruit oil, lavender oil, geranium maculatum oil, juniperus communis oil, cumen extract, sambucus nigra extract, caraway extract, sage extract, parsley extract, primula veris extract and phenoxyethanol and shearing the entire formulation.
30. A method of manufacturing a formulation, said method comprising:
shearing at least one emollient substance and at least one humectant substance;
adding at least one hydrolyzed whole egg to the oil phase of the mixture and then adding the oil phase to the water phase to form an emulsion; and
upon formation of the emulsion, cooling said formulation.
31. The method of claim 30 wherein said humectant substance is selected from a group consisting of glycerin, butylenes glycol, propylene glycol, pentylene glycol and mixtures thereof.
32. The method of claim 30 wherein said emollient substance is selected from a group consisting of Prunus Amygdalus Dulis (Sweet Almond) Oil, Squalene, Prunus Armeniaca (Apricot) Kernel Oil, Carthamus Tinetorius (Safflower) Oil, Helianthus Annuus (Sunflower) Seed Oil and extracts thereof and mixtures thereof.
33. The method of claim 30 wherein said formulation is a cosmetic formulation.
34. The method of claim 30 wherein said formulation is a cosmopharmaceutical formulation.
35. The method of claim 30 wherein said formulation is a pharmaceutical formulation.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/039,793 US20030003117A1 (en) | 2001-06-18 | 2002-01-08 | Hydrolyzed whole egg products & related methods |
| US10/260,344 US7094415B2 (en) | 2001-06-18 | 2002-10-01 | Skin care products containing whole egg |
| US11/294,838 US20060073211A1 (en) | 2001-06-18 | 2005-12-07 | Cellulite formulation containing whole egg |
| US11/328,399 US20060105005A1 (en) | 2002-01-08 | 2006-01-10 | Skin care formulation containing whole egg powder |
| US11/334,971 US20060105055A1 (en) | 2001-06-18 | 2006-01-20 | Arthritis and muscle soothing formulation containing whole egg powder |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29887401P | 2001-06-18 | 2001-06-18 | |
| US10/039,793 US20030003117A1 (en) | 2001-06-18 | 2002-01-08 | Hydrolyzed whole egg products & related methods |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/260,344 Continuation US7094415B2 (en) | 2001-06-18 | 2002-10-01 | Skin care products containing whole egg |
| US11/294,838 Continuation US20060073211A1 (en) | 2001-06-18 | 2005-12-07 | Cellulite formulation containing whole egg |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20030003117A1 true US20030003117A1 (en) | 2003-01-02 |
Family
ID=26716457
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/039,793 Abandoned US20030003117A1 (en) | 2001-06-18 | 2002-01-08 | Hydrolyzed whole egg products & related methods |
| US10/260,344 Expired - Fee Related US7094415B2 (en) | 2001-06-18 | 2002-10-01 | Skin care products containing whole egg |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/260,344 Expired - Fee Related US7094415B2 (en) | 2001-06-18 | 2002-10-01 | Skin care products containing whole egg |
Country Status (1)
| Country | Link |
|---|---|
| US (2) | US20030003117A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060083246A1 (en) * | 2004-10-19 | 2006-04-20 | Nvidia Corporation | System and method for processing RX packets in high speed network applications using an RX FIFO buffer |
| FR2929120A1 (en) * | 2008-03-28 | 2009-10-02 | Nutraveris Sarl | Composition, useful e.g. in dietary supplement, health food/fortified food, and for inducing e.g. weight loss, eliminating toxins and draining of mammal tissues, comprises caraway extract, meadowsweet extract, caffeine and Solidago extract |
| GB2469289A (en) * | 2009-04-07 | 2010-10-13 | Amtul Saleem Akhtar | Use of a combination of essential oils for the treatment of acne |
| US20130338078A1 (en) * | 2012-06-15 | 2013-12-19 | International Edge. Inc., | Skin care formulations including octapeptide complexes and methods for their manufacture |
| US8906426B2 (en) | 2011-11-16 | 2014-12-09 | Alyson Galderisi | Water-free, emulsifier-free, and preservative-free vehicle for active ingredients |
| CN108158891A (en) * | 2018-02-28 | 2018-06-15 | 陈平平 | A kind of skin care compositions for haze protection |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060073211A1 (en) * | 2001-06-18 | 2006-04-06 | Michael Marenick | Cellulite formulation containing whole egg |
| US20060105005A1 (en) * | 2002-01-08 | 2006-05-18 | Michael Marenick | Skin care formulation containing whole egg powder |
| US20060105055A1 (en) * | 2001-06-18 | 2006-05-18 | Michael Marenick | Arthritis and muscle soothing formulation containing whole egg powder |
| US20050266064A1 (en) * | 2004-05-29 | 2005-12-01 | Mccarthy Kathryn J | Cosmetic compositions and methods |
| US9028882B2 (en) | 2005-05-02 | 2015-05-12 | 4Life Patents, Llc | Nutraceutical gels |
| US10471100B2 (en) * | 2006-09-29 | 2019-11-12 | 4Life Patents, Llc | Nanofraction immune modulators, preparations and compositions including the same, and associated methods |
| CN104083408A (en) | 2005-05-02 | 2014-10-08 | 福莱专利有限责任公司 | Transfer factor preparations and associated methods |
| US20070042007A1 (en) * | 2005-08-19 | 2007-02-22 | Joseph Schwarz | Topical composition for delivery of salicylate esters |
| US20070059300A1 (en) * | 2005-09-12 | 2007-03-15 | Zoltan Laboratories Llc | Compounds and compositions to control abnormal cell growth |
| JP5967657B2 (en) * | 2009-10-20 | 2016-08-10 | ディスカバリー パートナーズ, エルエルシーDiscovery Partners, Llc | Skin cosmetic composition |
| SG194972A1 (en) | 2012-01-23 | 2013-12-30 | Restorsea Llc | Cosmetic |
| KR101293490B1 (en) * | 2012-03-16 | 2013-08-07 | 하월규 | Food compositon for inhibiting secretion of sebum and for reducing acne comprising egg white hydrolysate and lactoferrin |
| EP3091961A4 (en) | 2013-12-13 | 2017-11-15 | Restorsea, LLC | Exfoliative hair retention-promoting formulation |
| AU2015259509A1 (en) | 2014-05-16 | 2016-11-24 | Restorsea, Llc | Biphasic cosmetic |
| CN111265451A (en) * | 2020-04-01 | 2020-06-12 | 上海应用技术大学 | A kind of protein rejuvenation repair freeze-dried facial mask and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4223018A (en) * | 1979-02-09 | 1980-09-16 | Jimmie Belle | Bath composition |
| US4382967A (en) * | 1980-01-28 | 1983-05-10 | House Food Industrial Company Limited | Method for preparing porous saccharide granules and foods therefrom |
| FR2538248B1 (en) * | 1982-12-28 | 1986-08-22 | Interkemia Vegyipari Gazdasagi | STABILIZED COMPOSITIONS BASED ON QUAIL EGGS, ESPECIALLY FOR DOMESTIC USE |
-
2002
- 2002-01-08 US US10/039,793 patent/US20030003117A1/en not_active Abandoned
- 2002-10-01 US US10/260,344 patent/US7094415B2/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060083246A1 (en) * | 2004-10-19 | 2006-04-20 | Nvidia Corporation | System and method for processing RX packets in high speed network applications using an RX FIFO buffer |
| FR2929120A1 (en) * | 2008-03-28 | 2009-10-02 | Nutraveris Sarl | Composition, useful e.g. in dietary supplement, health food/fortified food, and for inducing e.g. weight loss, eliminating toxins and draining of mammal tissues, comprises caraway extract, meadowsweet extract, caffeine and Solidago extract |
| GB2469289A (en) * | 2009-04-07 | 2010-10-13 | Amtul Saleem Akhtar | Use of a combination of essential oils for the treatment of acne |
| GB2469289B (en) * | 2009-04-07 | 2011-05-25 | Amtul Saleem Akhtar | A composition of essential oils |
| US8906426B2 (en) | 2011-11-16 | 2014-12-09 | Alyson Galderisi | Water-free, emulsifier-free, and preservative-free vehicle for active ingredients |
| US20130338078A1 (en) * | 2012-06-15 | 2013-12-19 | International Edge. Inc., | Skin care formulations including octapeptide complexes and methods for their manufacture |
| WO2013188774A3 (en) * | 2012-06-15 | 2014-02-20 | International Edge Inc. | Skin care formulations including octapeptide complexes and methods for their manufacture |
| CN108158891A (en) * | 2018-02-28 | 2018-06-15 | 陈平平 | A kind of skin care compositions for haze protection |
Also Published As
| Publication number | Publication date |
|---|---|
| US20030133989A1 (en) | 2003-07-17 |
| US7094415B2 (en) | 2006-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7094415B2 (en) | Skin care products containing whole egg | |
| US20060105005A1 (en) | Skin care formulation containing whole egg powder | |
| Ashique et al. | A systemic review on topical marketed formulations, natural products, and oral supplements to prevent androgenic alopecia: a review | |
| EP0954278B1 (en) | Pharmaceutical compositions containing kukui nut oil | |
| JP3640392B2 (en) | Dermatological composition | |
| US20060188532A1 (en) | Mixture for transdermal delivery of low and high molecular weight compounds | |
| CA2518965A1 (en) | Homeopathic formulations useful for treating pain and/or inflammmation | |
| CN109431873B (en) | Composition for repairing and relieving skin inflammation | |
| BR112015005339B1 (en) | use of synsepalum dulcificum seed oil as an active ingredient | |
| US20060105055A1 (en) | Arthritis and muscle soothing formulation containing whole egg powder | |
| CA2540539A1 (en) | A mixture for transdermal delivery of low and high molecular weight compounds comprising an ethoxylated oil | |
| US20060073211A1 (en) | Cellulite formulation containing whole egg | |
| CN110974861B (en) | Blumea balsamifera oil liposome | |
| Jufri | Hair growth activity and safety test of ethosomal gel ethyl acetate fraction of nothopanax leaves (Nothopanax scutellarium merr.) | |
| CN105982882B (en) | A kind of externally applied drug and preparation process of optical active starting materials composition prescription therapeutic hemorrhoid | |
| JP4295841B2 (en) | Antiallergic topical agent | |
| RU2116790C1 (en) | Antiinfectious agent "repharm" for external using | |
| CN114129649A (en) | Cold compress gel capable of promoting skin barrier repair and nursing | |
| RU2282473C2 (en) | Curative-prophylactic pomade eliciting antiviral activity and method for its preparing | |
| Khan et al. | Formulation and evaluation of derma heal cream against wound and burn healing activity in streptozotocin-induced diabetic Wistar albino rat | |
| US20250108042A1 (en) | Donepezil delivery formulation | |
| Balasubramaniyam et al. | Development of ethosomal gel loaded with Terminalia chebula for effective treatment of arthritis. | |
| Khalsa | Frequently asked questions (FAQ) | |
| RU2216314C1 (en) | Cream-mask for dehydrated skin | |
| Shingala et al. | Development and Evaluation of Herbal Ointment for Skin Burn |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: L'AVENIR, LLC, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MARENICK, MICHAEL;GALDERISI, ALYSON;REEL/FRAME:012464/0603 Effective date: 20011019 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |